» Articles » PMID: 18936709

BPH Gene Expression Profile Associated to Prostate Gland Volume

Overview
Date 2008 Oct 22
PMID 18936709
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the current study was to analyze gene expression profiles in benign prostatic hyperplasia and to compare them with phenotypic properties. Thirty-seven specimens of benign prostatic hyperplasia were obtained from symptomatic patients undergoing surgery. RNA was extracted and hybridized to Affymetrix Chips containing 54,000 gene expression probes. Gene expression profiles were analyzed using cluster, TreeView, and significance analysis of microarrays softwares. In an initial unsupervised analysis, our 37 samples clustered hierarchically in 2 groups of 18 and 19 samples, respectively. Five clinical parameters were statistically different between the 2 groups: in group 1 compared with group 2, patients had larger prostate glands, had higher prostate specific antigen levels, were more likely to be treated by alpha blockers, to be operated by prostatectomy, and to have major irritative symptoms. The sole independent parameter associated with this dichotome clustering, however, was the prostate gland volume. Therefore, the role of prostate volume was explored in a supervised analysis. Gene expression of prostate glands <60 mL and >60 mL were compared using significance analysis of microarrays and 227 genes were found differentially expressed between the 2 groups (>2 change and false discovery rate of <5%). Several specific pathways including growth factors genes, cell cycle genes, apoptose genes, inflammation genes, and androgen regulated genes, displayed major differences between small and large prostate glands.

Citing Articles

IL-27/IL-27RA signaling may modulate inflammation and progression of benign prostatic hyperplasia via suppressing the LPS/TLR4 pathway.

Lo H, Yu D, Gao H, Tsai M, Chuang E Transl Cancer Res. 2022; 9(8):4618-4634.

PMID: 35117826 PMC: 8798123. DOI: 10.21037/tcr-20-1509.


Unraveling the dark matter, long non-coding RNAs, in male reproductive diseases: A narrative review.

Dehghan Tezerjani M, Kalantar S Int J Reprod Biomed. 2020; 18(11):921-934.

PMID: 33349800 PMC: 7749978. DOI: 10.18502/ijrm.v13i11.7959.


Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Liu D, Shoag J, Poliak D, Goueli R, Ravikumar V, Redmond D Nat Commun. 2020; 11(1):1987.

PMID: 32332823 PMC: 7181734. DOI: 10.1038/s41467-020-15913-6.


Transforming growth factor beta 1 impairs benign prostatic luminal epithelial cell monolayer barrier function.

Li F, Pascal L, Wang K, Zhou Y, Balasubramani G, OMalley K Am J Clin Exp Urol. 2020; 8(1):9-17.

PMID: 32211449 PMC: 7076294.


Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Strand D, Costa D, Francis F, Ricke W, Roehrborn C Differentiation. 2017; 96:49-61.

PMID: 28800482 PMC: 5669834. DOI: 10.1016/j.diff.2017.07.005.


References
1.
Kyprianou N, Benning C . Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000; 60(16):4550-5. View

2.
Harper M, Goddard L, Wilson D, Matenhelia S, Conn I, Peeling W . Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate. 1992; 20(3):243-53. DOI: 10.1002/pros.2990200309. View

3.
Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

4.
Tiniakos D, Mitropoulos D, Kyroudi-Voulgari A, Soura K, Kittas C . Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate. Urology. 2006; 67(1):204-8. DOI: 10.1016/j.urology.2005.07.045. View

5.
Festuccia C, Muzi P, Gravina G, Millimaggi D, Speca S, Dolo V . Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol. 2006; 30(1):193-200. View